Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension

Journal of Clinical Pharmacology

Volumn 51, Issue 6, 2011, Pages 933-942

  Bhad, Prafulla ^a   Ayalasomayajula, Surya ^b   Karan, Rajesh ^a   Leon, Selene ^b   Riviere, Gillies Jacques ^c   Sunkara, Gangadhar ^b   Jarugula, Venkateswar ^b  

^a NOVARTIS HEALTHCARE PVT LTD   (India)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Amlodipine; drug; hydrochlorothiazide; hypertensive patients; interaction; pharmacokinetics; valsartan

Indexed keywords

AMLODIPINE; AMYLASE; GLUCOSE; HYDROCHLOROTHIAZIDE; TRIACYLGLYCEROL LIPASE; VALSARTAN;

ADULT; AMYLASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES; VALINE;

EID: 79955797753     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010376963     Document Type: Article

References (28)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005 ; 365: 217-223 (Pubitemid 40138015)
2. Ong KL, Tso AWK, Lam KSL, Cheung BMY. Gender difference in blood pressure control and cardiovascular risk factors in Americans with diagnosed hypertension. Hypertensioni. 2008 ; 51: 1-7
3. Sturkenboom MC, Dieleman JP, Picelli G, et al. Prevalence and treatment of hypertensive patients with multiple concomitant cardiovascular risk factors in the Netherlands and Italy. J Hum Hypertens. 2008 ; 22: 704-713
4. Neal B, MacMohan S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet. 2000 ; 356: 1955-1964
5. Chobian AV, Bakris GL, Black HR, et al. The seventh report on the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003 ; 289: 2560-2571
6. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. Lancet. 1998 ; 351: 1755-1762 (Pubitemid 28269185)
7. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002 ; 4: 393-404 (Pubitemid 35469393)
8. Alleman Y, Fraile B, Lambert M, Barbier M, Ferber P, Izzo JL. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure After Single Therapy (EX-FAST) study. J Clin Hypertens. 2008 ; 10: 185-194
9. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002 ; 62: 443-462 (Pubitemid 34208333)
10. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003 ; 290: 199-206 (Pubitemid 37430058)
11. Black HR, Elliott WJ, Neaton JD, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension. 2001 ; 37: 12-18 (Pubitemid 32064233)
12. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007 ; 115: 2761-2788 (Pubitemid 46842793)
13. Khanna A, Lefkowitz L, White WB. Evaluation of recent fixed-dose combination therapies in the management of hypertension. Curr Opin Nephrol Hypertens. 2008 ; 17: 477-483
14. Kjeldsen SE, Jamerson KA, Bakris GL, et al. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH Study. Blood Press. 2008 ; 17: 7-17 (Pubitemid 351890487)
15. Jamerson K, Bakris GL, Dahlof B, et al. Exceptional early blood pressure control rates: the ACCOMPLISH Trial. Blood Press. 2007 ; 16: 80-86 (Pubitemid 47050368)
16. White WB, Giles T, Bakris GL, Neutel JM, Davidai G, Weber MA. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. Am Heart J. 2006 ; 151: 176-184 (Pubitemid 41815351)
17. Kjeldsen SE, Hedner T, Narkiewicz K, Oparil S. More is less? Optimal combination therapy for adequate blood pressure lowering in hypertension. Blood Press. 2008 ; 17: 132-133
18. Nash DT. Rationale for combination therapy in hypertension management: focus on angiotensin receptor blockers and thiazide diuretics. South Med J. 2007 ; 100: 386-392 (Pubitemid 46559168)
19. Plosker GL, Robinson DM. Amlodipine/valsartan: fixed dose combination in hypertension. Drugs. 2008 ; 68: 373-381 (Pubitemid 351225813)
20. Wagstaff AG. Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension. Drugs. 2006 ; 66: 1881-1901
21. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild-to-moderate essential hypertension. Clin Ther. 2007 ; 29: 563-580 (Pubitemid 47028551)
22. Hedner T, Kjeldsen SE, Narkiewicz K, Oparil S. Blood pressure control-slowly getting there through new strategies?. Blood Press. 2007 ; 16: 68-71 (Pubitemid 47050367)
23. White WB, Calhoun DA, Samuel R, Taylor AA, Zappe DH, Purkayastha D. Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? The Valsartan Hydrochlorothiazide Diuretic for Initial Control and Titration to Achieve Optimal Therapeutic Effect (Val-DICTATE) Trial. J Clin Hypertens. 2008 ; 10: 450-458
24. Chrysant SG, Chrysant C, Trus J, Hitchcock A. Antihypertensive effectiveness of amlodipine in combination with hydrochlorothiazide. Am J Hypertens. 1989 ; 2: 537-557
25. Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens. 2001 ; 14: 963-968 (Pubitemid 32862599)
26. Neldam S, Edwards C. Telmisartan plus HCTZ vs. amlodipine plus HTCZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study. Am J Geriatr Cardiol. 2006 ; 15: 151-160
27. Coulhan DA, Lacourciere Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan and hydrochlorthiazide: a randomized clinical trial. Hypertension. 2009 ; 54: 32-39
28. White WB. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension. Blood Press Monit. 2008 ; 13: 123-129 (Pubitemid 351416914)